Screener
Aktis Oncology, Inc. AKTS Q3 2026 earnings
Reported November 12, 2026 · Before market open
Revenue$3.9MMiss by $968.5K
EPS-$0.54Miss by $0.07
Revenue estimate$4.9M
EPS estimate-$0.47
Next report
Date not yet announcedVersus estimates
Revenue
Q3 2026$3.9MMiss by $968.5K
Q2 2026$3.4MBeat by $686.3KQ1 2026$3.2MBeat by $997.0KQ4 2024$1.7MMiss by $1.6MQ4 2025$4.6MDiluted EPS
Q3 2026-$0.54Miss by $0.07
Q2 2026-$0.44Miss by $0.01Q1 2026-$0.38Miss by $0.07Q4 2024-$1.27Beat by $20.32Q4 2025-$60.17FAQ
- When did Aktis Oncology, Inc. report Q3 2026 earnings?
- Aktis Oncology, Inc. (AKTS) reported Q3 2026 earnings on November 12, 2026 before market open.
- What were Aktis Oncology, Inc.'s Q3 2026 revenue and EPS?
- Aktis Oncology, Inc. reported revenue of $3.9M and eps of $-0.54 for Q3 2026.
- Did Aktis Oncology, Inc. beat estimates in Q3 2026?
- Revenue missed the consensus estimate of $4.9M by $968.5K. EPS missed the consensus estimate of $-0.47 by $0.07.
- Where can I find Aktis Oncology, Inc.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-457045) and the 10-Q periodic report (0001193125-26-457054) directly on SEC EDGAR. The filing index links above go to sec.gov.
